MAX001 / Maxion Therapeutics - LARVOL DELTA

Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody Pipeline and Platform (GlobeNewswire) - "Maxion Therapeutics...announced today that it has raised $72 million (£58 million) in a Series A financing. The financing reaffirms the potential of Maxion’s proprietary KnotBody technology and development pipeline and its opportunity to address large global markets....Financing led by General Catalyst with additional investment from new investors, British Patient Capital, Solasta Ventures and Eli Lilly and Company and supported by existing investors LifeArc Ventures, Monograph Capital and BGF; Proceeds will be used to transform Maxion into a clinical-stage biotech company, taking the lead KnotBody programme MAX001 to clinical proof-of-concept and advancing additional programmes towards the clinic."

Financing • Atopic Dermatitis • Inflammatory Bowel Disease